Related Experiment Video

Updated: Nov 22, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.9K

Targeting STAT3 by a small molecule suppresses pancreatic cancer progression

Huang Chen1, Aiwu Bian1, Lian-Fang Yang2

  • 1East China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, China.

Oncogene
|January 9, 2021
PubMed

Insights

A new small-molecule inhibitor, N4, effectively targets STAT3 signaling in pancreatic cancer. This compound suppressed tumor growth and metastasis in preclinical models, offering a promising therapeutic strategy for this lethal disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Pancreatic cancer is highly lethal, with limited effective treatments due to therapeutic resistance.
  • Signal transducer and activator of transcription 3 (STAT3) plays a crucial role in pancreatic cancer progression.
  • Targeting STAT3 offers a potential therapeutic avenue, but effective inhibitors are scarce.

Purpose of the Study:

  • To develop and evaluate a novel small-molecule inhibitor (N4) targeting STAT3 for pancreatic cancer treatment.
  • To investigate the mechanism of action of N4 in inhibiting oncogenic processes driven by STAT3.
  • To assess the preclinical efficacy and safety of N4 in animal models of pancreatic cancer.

Main Methods:

  • Fluorescence polarization (FP) assay to assess STAT3 and phospho-tyrosine (pTyr) peptide interactions.
  • Western blotting to evaluate STAT3 phosphorylation (Tyr705) and downstream gene expression.
  • In vitro assays to confirm N4 binding to the STAT3 SH2 domain and inhibition of STAT3 dimerization and cross-talk (STAT3-EGFR, STAT3-NF-κB).
  • In vivo studies using pancreatic cancer animal models to evaluate tumor growth, metastasis, survival, and tolerability of N4.

Main Results:

  • N4 effectively blocked STAT3 and pTyr peptide interactions in FP assays.
  • N4 specifically abolished STAT3 phosphorylation at Tyr705 and suppressed STAT3 downstream gene expression.
  • N4 directly binds to the STAT3 SH2 domain, inhibiting STAT3 dimerization and crucial cross-talk pathways.
  • N4 demonstrated well-tolerated administration, suppressed tumor growth and metastasis, and significantly prolonged survival in preclinical pancreatic cancer models.

Conclusions:

  • N4 is a potent small-molecule inhibitor with significant antitumor activity against pancreatic cancer.
  • N4 functions by directly inhibiting STAT3 signaling pathways, including dimerization and cross-talk.
  • N4 shows preclinical efficacy and tolerability, establishing it as a potential therapeutic candidate for pancreatic cancer.

More Related Videos

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

3.3K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.4K